My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

339.37 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023

October 06, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

September 13, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

September 13, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

September 07, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

3 Stocks to Buy For the COVID Resurgence

September 06, 2023

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

Via MarketBeat

Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna

August 25, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity

August 03, 2023

From Alnylam Pharmaceuticals

Via Business Wire

Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference

August 02, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk

July 24, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results

July 20, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine

July 19, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

July 17, 2023

From Alnylam Pharmaceuticals

Via Business Wire

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

June 30, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference

June 05, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy

May 20, 2023

From Alnylam

Via Business Wire

Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

May 04, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference

May 03, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Issues 2022 Corporate Responsibility Report

May 03, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

April 26, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

April 26, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Why Legend Biotech Stock Is Having Its Best Month Yet

April 25, 2023

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

Via MarketBeat

Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results

April 20, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Appointment of Peter Kellogg to Board of Directors

March 08, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

March 01, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity

February 23, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

February 21, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results

February 02, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates

January 08, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Updates to its Board of Directors

January 05, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.